The estimated Net Worth of Richard /Ca/ Murray is at least $4.56 Миллион dollars as of 4 April 2023. Richard Murray owns over 39,228 units of Jounce Therapeutics Inc stock worth over $354,905 and over the last 20 years he sold JNCE stock worth over $2,739,581. In addition, he makes $1,468,800 as President, Chief Executive Officer и Director at Jounce Therapeutics Inc.
Sign up
Richard Murray JNCE stock SEC Form 4 insiders trading
Richard has made over 21 trades of the Jounce Therapeutics Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he sold 39,228 units of JNCE stock worth $72,572 on 4 April 2023.
The largest trade he's ever made was exercising 86,482 units of Jounce Therapeutics Inc stock on 15 January 2021 worth over $41,511. On average, Richard trades about 14,003 units every 183 days since 2004. As of 4 April 2023 he still owns at least 188,779 units of Jounce Therapeutics Inc stock.
You can see the complete history of Richard Murray stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Richard Murray biography
Dr. Richard Murray, Ph.D. is the President, Chief Executive Officer and Director of the Company. Prior to joining Jounce, Dr. Murray served as senior vice president of biologics and vaccines research and development at Merck & Co., a global healthcare company, from 2009 to June 2014, where he was responsible for the advancement of biologics and vaccines, including Merck's cancer immunotherapy pipeline. Since June 2019, he has served as a director of Platelet Biogenesis, Inc., a private biotechnology company. Dr. Murray holds a Ph.D. in microbiology and immunology from the University of North Carolina at Chapel Hill and a B.S. in microbiology from the University of Massachusetts, Amherst.
What is the salary of Richard Murray?
As the President, Chief Executive Officer и Director of Jounce Therapeutics Inc, the total compensation of Richard Murray at Jounce Therapeutics Inc is $1,468,800. There are 1 executives at Jounce Therapeutics Inc getting paid more, with Kimberlee Drapkin having the highest compensation of $2,032,250.
How old is Richard Murray?
Richard Murray is 61, he's been the President, Chief Executive Officer и Director of Jounce Therapeutics Inc since 2014. There are 6 older and 9 younger executives at Jounce Therapeutics Inc. The oldest executive at Jounce Therapeutics Inc is Dr. Louis M. Weiner M.D., 69, who is the Founder.
What's Richard Murray's mailing address?
Richard's mailing address filed with the SEC is C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139.
Insiders trading at Jounce Therapeutics Inc
Over the last 8 years, insiders at Jounce Therapeutics Inc have traded over $39,574,093 worth of Jounce Therapeutics Inc stock and bought 724,587 units worth $10,288,083 . The most active insiders traders include Kevin Ctang Capital Managem..., Harbor Master Investors (Ca... и Rock Ventures Ii, L.P.Third.... On average, Jounce Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of $171,610. The most recent stock trade was executed by Richard /Ca/ Murray on 4 April 2023, trading 39,228 units of JNCE stock currently worth $72,572.
What does Jounce Therapeutics Inc do?
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce's highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce's internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce's most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce's broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc.
What does Jounce Therapeutics Inc's logo look like?
Complete history of Richard Murray stock trades at Jounce Therapeutics Inc и PDL Biopharma Inc
Jounce Therapeutics Inc executives and stock owners
Jounce Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Kimberlee Drapkin,
Chief Financial Officer, Treasurer -
Richard Murray,
President, Chief Executive Officer, Director -
Dr. Richard Murray,
Pres, CEO & Director -
Hugh Cole,
Chief Business Officer, Head of Corporate Development -
Elizabeth Trehu,
Chief Medical Officer -
Hugh M. Cole,
Chief Bus. Officer & Head of Corp. Devel. -
Kimberlee Cobleigh Drapkin CPA, CPA,
CFO & Treasurer -
Dr. Elizabeth G. Trehu,
Chief Medical Officer -
Perry Karsen,
Independent Chairman of the Board -
Barbara Duncan,
Independent Director -
J. Duncan Higgons,
Independent Director -
Luis Diaz,
Independent Director -
Cary Pfeffer,
Independent Director -
Robert Tepper,
Independent Director -
Robert Kamen,
Independent Director -
Robert Iannone,
Independent Director -
Dr. Stephen G. Farrand Ph.D.,
Chief Technical Officer -
Dr. Louis M. Weiner M.D.,
Founder -
Dr. Padmanee Sharma M.D., Ph.D.,
Founder -
Dr. Thomas F. Gajewski M.D., Ph.D.,
Founder -
Dr. Louis M. Weiner,
Founder -
Dr. Padmanee Sharma,
Founder -
Dr. Drew Mark Pardoll M.D., Ph.D.,
Founder -
Dr. Robert D. Schreiber,
Founder -
Dr. Thomas F. Gajewski,
Founder -
Dr. James P. Allison,
Founder -
Switzerland Llccelgene Corp...,
-
Rock Ventures Ii, L.P.Third...,
-
Harbor Master Investors (Ca...,
10% owner -
Biosciences, Llc Concentra,
10% owner -
Luisa Salter Cid,
Director -
Rock Ventures Ii, L.P.Third...,
-
Kevin Ctang Capital Managem...,
-
Jigar Raythatha,
Director -
Rock Ventures Iii, L.P.Thir...,